Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission
March 31st, 2009
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the European Medicines Agency (EMEA), with a positive opinion of the Committee for Orphan Medicinal Products, has granted orphan medicinal product designation to the Company’s novel antifolate, pralatrexate, for the treatment of non-papillary transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 study in patients with advanced or metastatic relapsed TCC of the urinary bladder. In April 2007, the EMEA granted orphan drug designation to pralatrexate for the treatment of patients with peripheral T-cell lymphoma. “This...
Source: Cancer Weekly (2009-03-31)
|
